STOCKS TELEGRAPH

Tag: NRIX Stock Price

  • Nurix (NRIX) Stock Jumps In After-Hour Trading Following Q2 Earnings Release

    Nurix (NRIX) Stock Jumps In After-Hour Trading Following Q2 Earnings Release

    Following a 7.94% increase during the regular session, when the stock finished at $13.18, Nurix Therapeutics, Inc. (NASDAQ: NRIX) showed great momentum in the extended trading session, rising 17.37% to $15.47.

    The company’s Q2 2025 financial results, which showed notable revenue growth and milestone accomplishments throughout its medicinal portfolio and partnerships, preceded the strong increase.

    Partnerships Drive Revenue Growth

    Nurix recorded $44.1 million in revenue for the fiscal quarter that concluded on May 31, 2025, a significant rise over the $12.1 million generated during the same period the previous year. A $30 million licensing payment from Sanofi as a result of two license agreements being extended and a $5 million milestone payment from Gilead were primarily responsible for this rise.

    The firm reported a net loss of $43.5 million, or ($0.52) per share, despite the upward sales trend. This was a slight improvement above the $44.5 million loss, or ($0.71) per share, in the previous year.

    Clinical Development and Regulatory Successes

    Several clinical and regulatory developments occurred throughout the quarter. Sanofi extended its license for the STAT6 program after Nurix achieved significant milestones, which resulted in an extra $15 million payment. With this extension, the Sanofi collaboration’s total payouts reached $127 million, with a further $465 million in possible future milestones.

    Gilead and Nurix also said that the FDA has approved the IND application for GS-6791 (NX-0479), a first-of-its-kind oral IRAK4 degrader intended to treat inflammatory and autoimmune disorders.

    Promising Clinical Data and EMA Recognition

    Nurix provided strong Phase 1 data for bexobrutideg (NX-5948) at EHA2025 and ICML-18. These data showed an objective response rate of 80.9% in patients with relapsed or refractory CLL, including a full response in a high-risk case.

    Additionally, bexobrutideg was given orphan drug status (ODD) by the European Medicines Agency (EMA) for lymphoplasmacytic lymphoma, providing strategic regulatory advantages inside the EU.

    Artificial Intelligence-Based Innovation

    At the AACR Annual Meeting, Nurix also demonstrated their DEL-AI platform, which uses a unique DNA-encoded library-based foundation model to speed up the discovery of new binders for challenging medicinal targets.

    Nurix’s growing portfolio of degraders and strategic partnerships highlight the company’s leadership in immunology and cancer therapeutic innovation as it enters a critical phase.

  • Nurix (NRIX) Shares Soar On Partnership Advancements

    Nurix (NRIX) Shares Soar On Partnership Advancements

    The current trajectory of Nurix Therapeutics, Inc. (NASDAQ: NRIX) stock exhibits a notable ascent in its market value. It is showcasing a substantial surge of 14.91% to $15.86 as of the last check during current market session. This remarkable elevation in the value of NRIX shares on the US stock charts ensues consequent to significant collaborative endeavors.

    Nurix (NRIX) has disclosed today an expansion of the ongoing research initiative with Sanofi, focusing on STAT6 (signal transducer and activator of transcription 6). STAT6 emerges as a pivotal pharmacological target in type 2 inflammation. It functions as a crucial transcription factor within the IL-4/IL-13 signaling pathways, pivotal drivers of inflammation in allergic conditions.

    Presently, these conditions are managed with injectable monoclonal antibody therapies designed to impede IL-4/IL-13 signaling. Preclinical data derived from Nurix’s STAT6 degraders evince that the targeted degradation of this critical transcription factor facilitates a swiftly acting and potent blockade of signaling. NRIX foresees the identification of a clinical candidate from this advanced preclinical program within the ensuing twelve months.

    The extension of the STAT6 research program with Sanofi underscores the triumph of our ongoing collaboration, amalgamating Nurix’s expertise in the design and advancement of targeted protein degraders with Sanofi’s industry-leading proficiencies in inflammation and immunology.

    Nurix will persist in its collaboration with Sanofi, thereby accentuating the efficacy of its enduring research program aimed at cultivating a pipeline of groundbreaking degraders to address inflammation and autoimmunity. Among the products revealed in Nurix’s pipeline for inflammation and autoimmunity are the BTK degrader NX-5948, which is exclusive to Nurix, the IRAK4 degrader with Gilead, and the STAT6 degrader with Sanofi.

    In adherence to the collaboration agreement, Nurix is leveraging its proprietary drug discovery platform to pinpoint novel agents that utilize E3 ligases to induce the degradation of specified drug targets. Sanofi retains the option to license resulting drug candidates, while Nurix preserves its option to co-develop and co-promote future products in the United States under programs for which Nurix has exercised its option.